Workshop: 3D model and applications in Oncology Preclinical MRI Imaging of liver colorectal

FERRER Cyril
Workshop: 3D model
and applications in
Oncology
Toulouse, 26/06/2014
1
Institut de Recherche en Cancérologie de Montpellier (IRCM)
&
Laboratoire Charles Coulomb (L2C)
Preclinical MRI Imaging of liver colorectal
metastases

Colorectal Cancer (CRC)
2
❖Incidence:
❖3rd most common cancer worldwide
❖4th most common cause of death
❖In France in 2012, Second in women and men
❖Prevision in France: 45 000 new cases every year in
2020
❖50 % of CRC metastases in liver

Risk Factors
3
❖Familial and heredital (Adenomatous Polyposis, Hereditary
nonpolyposis Colon cancer…)
❖Age: 90% colon cancer patients are diagnosed after the
age of 50.
❖Diet, physical inactivity, smoking & alcohol consumption
❖Inflammatory Bowel Disease (IBD)
❖Obesity type 2 diabetes

Colorectal Cancer
❖Treatment :
❖Depends on the stage:
❖0 and I: Surgery
❖II and III: Surgery, if needed:
radiotherapy, chemotherapy
❖IV: Mainly chemotherapy
❖Five-year survival rate: 56%
❖90% if early detection (American Cancer
Society)
4

How to improve this survival
rate?
❖Pre-clinical imaging allow us to try to improve:
❖Earlier detection
❖Functional acquisition
❖But also :
❖Evaluate new treatments
❖Evaluate combination of therapies (time, dose):
❖chemotherapy (FUFOL, FOLFOX, XELOX, FOLFIRI)
❖anti-angiogenic drugs (Avastin anti-VEGF, Erbitux anti-EGFR)
5